These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 24861209)

  • 1. An investigation of the genetic basis of increased susceptibility to neutralization by anti-fusion glycoprotein antibody arising on passage of human respiratory syncytial virus in cell culture.
    Hiriote W; Gias EL; Welsh SH; Toms GL
    J Med Virol; 2015 Jan; 87(1):130-40. PubMed ID: 24861209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
    Marsh R; Connor A; Gias E; Toms GL
    J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein.
    Tomé L; Frabasile S; Candia C; Pittini A; Farina N; Melero JA; Arbiza J
    Arch Virol; 2012 Jun; 157(6):1071-80. PubMed ID: 22411099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and Significance of Substitutions in the Fusion Protein of Respiratory Syncytial Virus Resulting in Neutralization Escape From Antibody MEDI8897.
    Zhu Q; Lu B; McTamney P; Palaszynski S; Diallo S; Ren K; Ulbrandt ND; Kallewaard N; Wang W; Fernandes F; Wong S; Svabek C; Moldt B; Esser MT; Jing H; Suzich JA
    J Infect Dis; 2018 Jul; 218(4):572-580. PubMed ID: 29617879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus.
    Liu C; Day ND; Branigan PJ; Gutshall LL; Sarisky RT; Del Vecchio AM
    Virol J; 2007 Jul; 4():71. PubMed ID: 17623075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.
    Palomo C; Mas V; Detalle L; Depla E; Cano O; Vázquez M; Stortelers C; Melero JA
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6498-6509. PubMed ID: 27550346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity in mice of human metapneumovirus with a truncated SH glycoprotein.
    Tedcastle AB; Fenwick F; Robinson MJ; Toms GL
    J Med Virol; 2014 Apr; 86(4):547-57. PubMed ID: 24009128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus neutralization assays for human respiratory syncytial virus using airway organoids.
    van Dijk LLA; Rijsbergen LC; Rubio BT; Schmitz KS; Gommers L; Comvalius AD; Havelaar A; van Amerongen G; Schepp R; Lamers MM; GeurtsvanKessel CH; Haagmans BL; van Binnendijk R; de Swart RL; de Vries RD
    Cell Mol Life Sci; 2024 Jun; 81(1):267. PubMed ID: 38884678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein.
    Crowe JE; Firestone CY; Crim R; Beeler JA; Coelingh KL; Barbas CF; Burton DR; Chanock RM; Murphy BR
    Virology; 1998 Dec; 252(2):373-5. PubMed ID: 9878616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation.
    Palomo C; Mas V; Vázquez M; Cano O; Luque D; Terrón MC; Calder LJ; Melero JA
    Virology; 2014 Jul; 460-461():119-27. PubMed ID: 25010277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.
    Bates JT; Keefer CJ; Slaughter JC; Kulp DW; Schief WR; Crowe JE
    Virology; 2014 Apr; 454-455():139-44. PubMed ID: 24725940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein.
    Martínez I; Melero JA
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2215-20. PubMed ID: 9747731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization susceptibility of African swine fever virus is dependent on the phospholipid composition of viral particles.
    Gómez-Puertas P; Oviedo JM; Rodríguez F; Coll J; Escribano JM
    Virology; 1997 Feb; 228(2):180-9. PubMed ID: 9123824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.
    Bates JT; Keefer CJ; Utley TJ; Correia BE; Schief WR; Crowe JE
    J Immunol; 2013 Apr; 190(7):3732-9. PubMed ID: 23455501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches.
    Wu SJ; Schmidt A; Beil EJ; Day ND; Branigan PJ; Liu C; Gutshall LL; Palomo C; Furze J; Taylor G; Melero JA; Tsui P; Del Vecchio AM; Kruszynski M
    J Gen Virol; 2007 Oct; 88(Pt 10):2719-2723. PubMed ID: 17872524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.
    Magro M; Andreu D; Gómez-Puertas P; Melero JA; Palomo C
    J Virol; 2010 Aug; 84(16):7970-82. PubMed ID: 20534864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Susceptibilities of Respiratory Syncytial Virus to Nucleolin Receptor Blocking and Antibody Neutralization are Dependent upon the Method of Virus Purification.
    Bilawchuk LM; Griffiths CD; Jensen LD; Elawar F; Marchant DJ
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28771197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and epitope mapping of a sub-group cross-reactive anti-respiratory syncytial virus G glycoprotein monoclonal antibody which is protective in vivo.
    Robinson MJ; Tan CS; Fenwick F; Chambers CJ; Routledge EG; Toms GL
    J Med Virol; 2014 Jul; 86(7):1267-77. PubMed ID: 24415460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.